No internet connection — showing the saved version of the page.

Cellectis SA

USUSD
← to the screener

Cellectis SA (PA:ALCLS) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
cellectis.com
Investor relations
cellectis.com/en/investors/governance/
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Headquarters
France, France
CEO
Andre Choulika
Employees
224
Founded
1999
Shares outstanding
72.72 M
Free float
48.58 M
Market cap
148.06 M USD
Insiders
0%
Institutions
15.36%
Industry (SIC)
Biological Products, (No Diagnostic Substances)
Legal form
QVPB
ISIN
FR0010425595
LEI
5493000KKX5VQ37Q2W83
P/E
loss
FCF
−41.8 M USD
Debt
?
Earnings and FCF — for the 12 months to 31.12.2025 (the company's latest report).
NAV
1.04 USD · P/NAV 1.07
Balance sheet date31.12.2025
Assets325 M USD
− Liabilities249 M USD
= NAV (equity of the company's shareholders)75.9 M USD
− Intangible assets535 K USD
= Tangible NAV75.4 M USD
Shares72 718 974
NAV per share1.04 USD
Tangible NAV per share1.04 USD
Share price (ALCLS)0.9515 EUR
P/NAV1.07
NAV history
Balance sheet dateNAVNAV per share
31.12.202575.9 M USD1.04 USD
31.12.2024131 M USD1.80 USD
31.12.202384.7 M USD1.18 USD
30.09.202376.1 M USD1.05 USD
30.06.202396.6 M USD1.33 USD
31.12.2022118 M USD1.29 USD
31.12.2021221 M USD4.87 USD
31.12.2020284 M USD6.63 USD
Description

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksCMVLF OTCUSD3.47 +12.66%common stock
LSE London Stock Exchange0WA2 IOBEUR2.65 +0.00%common stock
PA Euronext ParisALCLS primaryEUR0.9515 -7.89%common stock

Price for 3 months

up day down dayHover / tap a day — open, close, high and low prices

Top holders

HolderStakeSharesReport date
B Group, Inc.4.55%3.28 M2026-06-30
Long Focus Capital Manag…3.8%2.74 M2026-06-30
UBS AM, a distinct busin…3.67%2.64 M2026-06-30
iShares Trust-iShares Bi…0.33%235 6962026-08-31
Nomura Asset Management…0.31%226 8752026-06-30
Delaware Group Equity Fu…0.31%226 8752026-06-30
Blackrock Inc.0.31%225 4442026-06-30
Morgan Stanley0.12%85 4552026-06-30
LPL Financial LLC0.12%84 4152026-06-30
Susquehanna Internationa…0.07%50 4532026-06-30
BNP Paribas Financial Ma…0.06%40 1002026-06-30
UBS Group AG0.05%33 9262026-06-30
Fidelity Concord Street…0%1 9492026-07-31